Sectors
ABOS
Acumen Pharmaceuticals, Inc.
2.85
2 x 2.17
1 x 2.92
bid
ask
-
0.07
2.40%
2 @ 05:54 PM
2.89 +0.04 (1.40%)
| Ytd | 35.07% | |
| 1y | 109.56% |
2.76
day range
2.92
1.21
52 week range
3.60
| Open | 2.90 | Prev Close | 2.92 | Low | 2.76 | High | 2.92 | Mkt Cap | 206.10M |
| Vol | 244.21K | Avg Vol | 471.18K | EPS | -1.64 | P/E | N/A | Forward P/E | -1.17 |
| Beta | 0.04 | Short Ratio | 6.61 | Inst. Own | 78.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 2.51 | 200-d Avg | 2.41 | 1yr Est | 10.80 |
| Income Statement | |||
| Operating Expenses | 32.56M | ||
| Research and Development Expense | 27.81M | ||
| Selling, General and Administrative Expense | 4.75M | ||
| Operating Income | -32.56M | ||
| Interest Expense | 1.09M | ||
| Net Income | -32.72M | ||
| Net Income Common Stock | -32.72M | ||
| Net Income Common Stock (USD) | -32.72M | ||
| Consolidated Income | -32.72M | ||
| Earnings per Basic Share | -0.45 | ||
| Earnings per Basic Share (USD) | -0.45 | ||
| Earnings per Diluted Share | -0.45 | ||
| Earning Before Interest & Taxes (EBIT) | -31.62M | ||
| Earning Before Interest & Taxes (USD) | -31.62M | ||
| Weighted Average Shares | 72.25M | ||
| Weighted Average Shares Diluted | 72.25M | ||
| Balance Sheet | |||
| Cash and Equivalents | 59.67M | ||
| Cash and Equivalents (USD) | 59.67M | ||
| Investments | 50.75M | ||
| Investments Current | 50.75M | ||
| Current Assets | 115.51M | ||
| Total Assets | 116.01M | ||
| Debt Current | 19.67M | ||
| Total Debt | 31.57M | ||
| Current Liabilities | 46.85M | ||
| Debt Non-Current | 11.90M | ||
| Total Liabilities | 58.74M | ||
| Accumulated Retained Earnings (Deficit) | -499.92M | ||
| Accumulated Other Comprehensive Income | -13.00K | ||
| Shareholders Equity | 57.26M | ||
| Shareholders Equity (USD) | 57.26M | ||
| Assets Non-Current | 494.00K | ||
| Total Debt (USD) | 31.57M | ||
| Liabilities Non-Current | 11.90M | ||
| Trade and Non-Trade Payables | 13.38M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 45.00K | ||
| Net Cash Flow from Financing | -278.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 7.65M | ||
| Issuance (Purchase) of Equity Shares | -278.00K | ||
| Net Cash Flow from Investing | 26.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 26.00M | ||
| Net Cash Flow from Operations | -18.07M | ||
| Share Based Compensation | 2.52M | ||